% | $
Quotes you view appear here for quick access.

Arrowhead Research Corp. Message Board

  • colleteqjknoll colleteqjknoll Oct 8, 2013 10:06 AM Flag


    CNBC just did a documentary on ARWR and the power of research reports sites, and new technology being used to scan the markets via research reports. Savvy investors that follow research reports are often statistically ahead of the street by DAYS, this can often translate into millions in potential profits. They mentioned that flash market research (google them ), a site I can vouch and have personally profited over $190k net profits, is now using this technology. This could change the markets for ARWR and all public companies!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • There's nothing on CNBC about Arrowhead. Nada, nil, zip. You made $190 thousand dollars using research reports? Really? That's a neat trick. I always find it amusing reading the message boards for all these 'obvious' pump-and-dump stocks. If you follow real research you can plainly see that the management of each company opens up with some fantastical technology, goes long enough to transfer equity into a holding company and then bankrupts itself. Then it repeats the same process by creating a new company to accumulate wealth by selling worthless shares and transferring profits from share sales into another holding company--all with the same management personnel. Over and over. Spin, wash, repeat. Anyone reading reports on the internet without actually visiting these companies is just throwing money away. You go ahead and vouch for total horsesh*t, it's your prerogative.

      • 1 Reply to thecktan
      • I have visited arrowhead. I'm lucky enough to live just outside of Madison Wisconsin, their research facility is just 20 minutes from my driveway. My wife works at a local hospital and I know people that are employed at the University of Wisconsin. Arrowheads research facility is second to none. No microcap stock has any business having a research facility of this quality. All thanks to Roche for being incompetent, this top-notch team landed in arrowhead's lap for pennies on the dollar . Did I mention I'm long Arrowhead pharmaceuticals?

    • While pricing the offering at market rates is a positive signal, why wouldn't they wait for the Phase I data (assuming that it remains sealed)?

    • You'r talking about spam.

6.70-0.13(-1.90%)Oct 21 4:00 PMEDT